Publications

Found 4 results
Filters: Author is Zask, Arie  [Clear All Filters]
2022
Liu, H., Iketani, S., Zask, A., Khanizeman, N., Bednarova, E., Forouhar, F., Fowler, B., Hong, S. Jung, Mohri, H., Nair, M. S., Huang, Y., Tay, N. E. S., Lee, S., Karan, C., Resnick, S. J., Quinn, C., Li, W., Shion, H., Xia, X., Daniels, J. D., Bartolo-Cruz, M., Farina, M., Rajbhandari, P., Jurtschenko, C., Lauber, M. A., McDonald, T., Stokes, M. E., Hurst, B. L., Rovis, T., Chavez, A., Ho, D. D., and Stockwell, B. R. (2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 13, 1891
Reglero, C., Dieck, C. L., Zask, A., Forouhar, F., Laurent, A. P., Lin, W. - H. W., Albero, R., Miller, H. I., Ma, C., Gastier-Foster, J. M., Loh, M. L., Tong, L., Stockwell, B. R., Palomero, T., and Ferrando, A. A. (2022) Pharmacological inhibition of NT5C2 reverses genetic and non-genetic drivers of 6-MP resistance in acute lymphoblastic leukemia. Cancer Discov. 10.1158/2159-8290.CD-22-0010
2021
Iketani, S., Forouhar, F., Liu, H., Hong, S. Jung, Lin, F. - Y., Nair, M. S., Zask, A., Huang, Y., Xing, L., Stockwell, B. R., Chavez, A., and Ho, D. D. (2021) Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat Commun. 12, 2016
2017
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., Tran, T. H., Akkiraju, H., Brown, L. M., Nandakumar, R., Cremers, S., Yang, W. Seok, Tong, L., Olive, K. P., Ferrando, A., and Stockwell, B. R. (2017) Multivalent Small-Molecule Pan-RAS Inhibitors. Cell. 168, 878-889.e29